Precision Alzheimer's Therapies: Predicting Who Benefits and Safeguards
Official title: Precision Alzheimer's Therapeutics Program
Funded at Brigham and Women's Hospital · NIH-11465221 · Data updated 2026-11-12
A new program at Brigham and Women’s Hospital aims to find blood and genetic markers that predict who will benefit most from anti-amyloid medications for Alzheimer's disease and who might have side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 15, 2026 |
| Project end | April 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $751,786 |
| NIH project number | 1R01AG093729-01A1 |
| Project ID | NIH-11465221 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals with Alzheimer's disease or related dementia who are considering anti-amyloid therapy and are willing to provide blood samples and genetic information for research.
✕Less likely to help
Patients not receiving anti-amyloid therapy or those without ready access to biomarker testing may see limited direct benefit.
What this research studies
This project focuses on people with Alzheimer's-related dementia and those at risk, using blood tests and genetic information to identify markers that forecast treatment response and safety with anti-amyloid therapies. Researchers will analyze genetic data and blood-based biomarkers to predict both efficacy (how well Aβ lowering helps) and risks like ARIA-related side effects. The work will help clinicians tailor anti-Aβ treatment choices and monitoring strategies to individual patients, potentially reducing unnecessary treatments and imaging. By making prediction more affordable and accessible, the study aims to improve outcomes while conserving healthcare resources.
Why it matters
Potential benefit: If successful, patients could receive more personalized anti-amyloid therapy with better outcomes and safer monitoring.
How similar studies have gone: Prior studies show that biomarkers can help predict treatment response and risk, but this program seeks to define robust genetic and plasma markers for anti-Aβ therapy.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Yang, Hyun-Sik — Brigham and Women's Hospital
- Study coordinator: Yang, Hyun-Sik
Related research
Other NIH-funded projects on the same topics.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
Statins to Prevent Cancer-Associated Blood Clots in Cancer Patients
A large study will test whether taking rosuvastatin every day for a year can lower the chance of dangerous blood clots in people with cancer, without raising the risk of bleeding.
-
Preterm infant body composition and early-life health after NICU stay
This grant studies how body composition in very preterm babies relates to later brain development and risk of obesity or diabetes, with findings meant to improve care from NICU through early childhood.
-
Rapid Emergency Skills for Prehospital Optimization and Delivery (RESPOND) for Guatemala
A lightweight, AI-enabled prehospital training and triage program helps volunteer firefighters in Guatemala deliver faster, better care to trauma patients.
-
Rapid Emergency Skills for Prehospital Optimization and Notification in Guatemala
A mobile, AI-powered training and triage program helps volunteer emergency responders in Guatemala provide faster, safer trauma care and notify hospitals more quickly.
-
Understanding antibiotic allergy to improve care for patients
Scientists are testing new ideas to understand why some people develop severe allergic reactions to antibiotics and how to prevent or treat them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.